ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025

Rhea-AI Summary

ImmuCell (Nasdaq: ICCC) will report unaudited financial results for the quarter and year ended December 31, 2025 after market close on March 4, 2026. The company will host a conference call on March 5, 2026 at 9:00 AM ET to review results.

Dial-in numbers, replay access (code #2017737) available through March 12, 2026. ImmuCell expects no change to preliminary sales disclosed January 8, 2026 and plans to file its Form 10-K on or before March 31, 2026.

Key Figures

Results release date: March 4, 2026 Earnings call time: 9:00 AM ET Replay end date: March 12, 2026 +2 more

5 metrics

Results release date March 4, 2026 Unaudited Q4 and FY 2025 results after market close

Earnings call time 9:00 AM ET Conference call on March 5, 2026

Replay end date March 12, 2026 Teleconference replay availability

Replay access code 2017737 Conference call replay code

Form 10-K filing deadline On or before March 31, 2026 Expected filing of Annual Report on Form 10-K

Market Reality Check

Price: $6.24 Vol: Volume 21,556 is roughly ...

normal vol

$6.24 Last Close

Volume Volume 21,556 is roughly in line with the 20-day average 19,358 (relative volume 1.11x). normal

Technical Price $6.24 is trading slightly above the 200-day MA $6.14 despite today’s decline.

Peers on Argus

ICCC is down 5.45% while key biotech peers show mixed moves; only KPTI appears i...

1 Up

ICCC is down 5.45% while key biotech peers show mixed moves; only KPTI appears in momentum scans, moving up, suggesting today’s action looks stock-specific rather than sector-driven.

Previous Earnings date Reports

1 past event · Latest: Nov 06 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	Move	Catalyst
Nov 06	Earnings date set	Neutral	-3.3%	Announced Q3 2025 results release date and conference call logistics.

Pattern Detected

Prior earnings date news saw a negative -3.33% move despite neutral scheduling content, suggesting a tendency for modest selling into these announcements.

Recent Company History

Over recent months, ImmuCell has reported shifting dynamics between its First Defense® and Re-Tain® programs, including preliminary Q4 and FY 2025 sales, an FDA Incomplete Letter for Re-Tain®, and a strategic refocus toward First Defense®. Earlier, Q3 2025 earnings showed improved margins and a swing to nine‑month net income. The prior earnings date release on Nov 6, 2025 simply set the schedule for Q3 results and reaffirmed preliminary sales. Today’s announcement similarly schedules release of full Q4 and FY 2025 unaudited results and related calls.

Historical Comparison

-3.3% avg move · Past earnings-date announcements for ICCC saw an average move of -3.33%. Today’s scheduling release ...

earnings date

-3.3%

Average Historical Move earnings date

Past earnings-date announcements for ICCC saw an average move of -3.33%. Today’s scheduling release for Q4 and FY 2025 mirrors that prior neutral, logistics-focused communication.

The company again follows its pattern of confirming preliminary sales first, then setting a date and call for full unaudited Q4 and full-year results, similar to the Q3 2025 earnings-date process.

Market Pulse Summary

This announcement sets expectations around timing for ImmuCell’s unaudited Q4 and full‑year 2025 res...

Analysis

This announcement sets expectations around timing for ImmuCell’s unaudited Q4 and full‑year 2025 results and confirms a conference call and replay window, plus an anticipated Form 10-K filing by March 31, 2026. In recent months, the company has reported preliminary FY 2025 sales and detailed a strategic shift toward First Defense®. Investors may watch how full results reconcile with January’s preliminary figures and how management frames progress on that strategic transition.

Key Terms

form 10-k

1 terms

form 10-k regulatory

"The Company expects to file its Annual Report on Form 10-K on or before Tuesday, March 31, 2026."

A Form 10-K is a comprehensive report that publicly traded companies are required to file annually with regulators. It provides a detailed overview of a company's financial health, operations, and risks, similar to a detailed health report. Investors use this information to assess the company's performance and make informed decisions about buying or selling its stock.

AI-generated analysis. Not financial advice.

Conference Call Scheduled for Thursday, March 5, 2026 at 9:00 AM ET

PORTLAND, Maine, Feb. 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, expects to report unaudited financial results for the quarter and year ended December 31, 2025 after the market closes on Wednesday, March 4, 2026.

The Company is planning to host a conference call the next morning, Thursday, March 5, 2026, at 9:00 AM ET to review the unaudited financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. A teleconference replay of the call will be available until March 12, 2026 at (855) 669-9658 (toll free) or (412) 317-0088 (international), utilizing replay access code #2017737.

The Company anticipates no change to the preliminary sales results for the quarter and year ended December 31, 2025 that were disclosed on January 8, 2026. The Company expects to file its Annual Report on Form 10-K on or before Tuesday, March 31, 2026.

About ImmuCell:
ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically proven and practical products that improve cattle health and productivity. ImmuCell manufactures and markets First Defense^®, providing Immediate Immunity™ to newborn dairy and beef calves. Press releases and other information about the Company are available at: http://www.immucell.com.

Contacts:	Olivier te Boekhorst, President and CEO
	Timothy C. Fiori, Chief Financial Officer
	ImmuCell Corporation
	investor.relations@immucell.com
	Joe Diaz, Robert Blum and Joe Dorame
	Lytham Partners, LLC
	iccc@lythampartners.com

FAQ

When will ImmuCell (ICCC) release unaudited results for the quarter and year ended December 31, 2025?

ImmuCell will release unaudited results after market close on March 4, 2026. According to the company, the formal review will occur on a conference call the following morning, March 5, 2026 at 9:00 AM ET.

How can investors join the ImmuCell (ICCC) conference call on March 5, 2026?

Dial (844) 855-9502 (U.S. toll free) or (412) 317-5499 (international) at 9:00 AM ET on March 5, 2026. According to the company, those numbers provide live access to the results review.

Is there a replay available for the ImmuCell (ICCC) March 5, 2026 conference call?

Yes. A teleconference replay is available until March 12, 2026 using access code #2017737. According to the company, replay numbers are (855) 669-9658 (U.S.) and (412) 317-0088 (international).

Will ImmuCell (ICCC) change its preliminary sales disclosed on January 8, 2026?

The company anticipates no change to the preliminary sales for the quarter and year ended December 31, 2025. According to the company, the final unaudited results are expected to align with that disclosure.

When does ImmuCell (ICCC) expect to file its Annual Report on Form 10-K for 2025?

ImmuCell expects to file its Form 10-K on or before March 31, 2026. According to the company, this filing will report audited annual information following the unaudited results announcement.